1. Background {#sec1-molecules-22-00525}
=============

Over the past several decades, much work has been done to overcome the skin barrier for drug penetration and increase the number of drugs available for transdermal administration, mainly relating to the skin´s stratum corneum (SC) \[[@B1-molecules-22-00525],[@B2-molecules-22-00525],[@B3-molecules-22-00525],[@B4-molecules-22-00525],[@B5-molecules-22-00525],[@B6-molecules-22-00525]\]. This work mainly includes the development of chemical penetration enhancement, physical enhancement, and biochemical enhancement methods for transdermal drug delivery. Common examples are chemical penetration enhancers (CPEs) \[[@B1-molecules-22-00525],[@B7-molecules-22-00525]\], sonophoresis \[[@B8-molecules-22-00525],[@B9-molecules-22-00525]\], iontophoresis \[[@B1-molecules-22-00525],[@B10-molecules-22-00525],[@B11-molecules-22-00525]\] and microneedles \[[@B3-molecules-22-00525],[@B10-molecules-22-00525],[@B11-molecules-22-00525],[@B12-molecules-22-00525]\]. However, to date, the transdermal delivery for most drugs remains a significant challenge due to low permeation rates \[[@B10-molecules-22-00525]\], in particular for larger molecular weight drugs.

Cupping therapy is one of the five traditional Chinese medicine (TCM) therapies (which are medicine, acupuncture, moxibustion, massage, and cupping), and the earliest ancient records about cupping therapy can be traced back to *Prescriptions of Fifty-two Diseases* from the period of the Tang Dynasty, which are documents about the treatment of diseases using "horn cups" (made of ox horn). Fu's cupping therapy (FCT) marks the comprehensive modernization, innovation, and development of TCM cupping therapy ([Figure 1](#molecules-22-00525-f001){ref-type="fig"} and [Figure 2](#molecules-22-00525-f002){ref-type="fig"}). It encloses and creates a confined space between the body skin (or mucosa) and the walls of the cup through the FCT effect, which shapes and serves as an artificial environment producing various stimulating effects on human skin and subcutaneous structure. Multiple physical, chemical, and biological effect parameters within the cup cavity, such as pressure, temperature, and O~2~ and CO~2~ amounts, can be observed and regulated through its observation and regulation slots on the cup, respectively. Since the cup cavity is artificially constructed and presses on the body, it is referred to as "artificial near-body microenvironment full regulation therapy", namely through the theory of "generalized meridian: 3 fields and 2 cavities--gap", forming part of TCM theories. Furthermore, several effects of FCT as a TCM treatment on the human body, especially on the skin, have been revealed via modern research. Among them, several aspects may support and interpret the idea of FCT being used as a method of enhanced drug penetration.

Based on the above, we focused on a preliminary exploration of utilizing FCT and creating a new physical technology for transdermal administration with TCM characteristics. A 1-(4-chlorobenzoyl)-5-methoxy-2-methylindole-3-ylacetic acid (indomethacin, a model drug) hydrophilic gel patch \[[@B13-molecules-22-00525],[@B14-molecules-22-00525]\] was prepared as preparations for transdermal administration, while naproxen acted as an internal standard. Firstly, compared with CPEs (as references, including Azone and mint oil) and iontophoresis, FCT penetration enhancement was divided into three groups ([Table 1](#molecules-22-00525-t001){ref-type="table"}): the FCT low-intensity group (FCTL), the FCT middle-intensity group (FCTM), and the FCT high-intensity group (FCTH). Their penetration effects on indomethacin hydrophilic gel patches were evaluated through in vitro and in vivo transdermal penetration enhancement tests, in which in vitro transdermal parameters and in vivo pharmacokinetic parameters were used as detection indices. Posteriorly, the synergism between FCT physical penetration technology and chemical penetration enhancers (regarding the various CPE ratios) in transdermal enhancement was investigated first, utilizing 3^K^ factorial design and ultra-performance liquid chromatography-tandem mass spectrometry technologies (UPLC-MS/MS). Furthermore, skin treated with chemical penetration enhancers, iontophoresis, and FCT, obtained from in vitro skin penetration studies, was examined via scanning electron microscopy (SEM) \[[@B15-molecules-22-00525],[@B16-molecules-22-00525]\] and transmission electron microscopy (TEM) \[[@B5-molecules-22-00525],[@B9-molecules-22-00525],[@B15-molecules-22-00525],[@B16-molecules-22-00525],[@B17-molecules-22-00525],[@B18-molecules-22-00525],[@B19-molecules-22-00525],[@B20-molecules-22-00525]\] to investigate the effect of FCT physical penetration technology on ultrastructural skin changes, especially its SC, and to tentatively and preliminarily evaluate the mechanism by which FCT enhances skin penetration.

2. Methods {#sec2-molecules-22-00525}
==========

2.1. Materials {#sec2dot1-molecules-22-00525}
--------------

Indomethacin and naproxen references (purity \> 99.9%, determined by high performance liquid chromatography) were obtained from the Chinese National Institutes for Food and Drug Control. HPLC-grade acetonitrile, methanol, and formic acid were obtained from Tedia Company Incorporation (Fairfield, OH, USA), and medical Azone and mint oil were purchased from Tianjin Kemiou Chemical Reagent Co., Ltd. (Tianjin, China). Double-distilled water was purified through a Milli-Q water purification system (Millipore, Billerica, MA, USA), and indomethacin hydrophilic gel patches were prepared and supplied by the Preparation Laboratory of Guiyang College of Traditional Chinese Medicine. Hydrophilic gel matrix materials, used to prepare indomethacin patches, were purchased from Shanghai Ye Source Biotechnology Co., Ltd. (Shanghai, China). Finally, Sprague-Dawley (SD) rats, weighing 320 to 350 g, were supplied by the Experimental Animal Center of Third Military Medical University (Chongqing, China).

2.2. Preparation of Indomethacin Patches {#sec2dot2-molecules-22-00525}
----------------------------------------

We identified the prescription of the indomethacin matrix by screening and optimization: its composition was 17.350 g of polyvinyl alcohol (PVA), 9.999 g of gelatin, 6.260 g of polyvinyl pyrrolidone (PVPK-30), 8.140 g of sodium carboxyl methyl cellulose (CMC-Na), 3.000 g of carbomer-940, 12.880 g of glycerol, 12.880 g of propylene glycol, and 4.200 g of triethanolamine.

The preparation process of matrix patches was as follows: firstly, PVA and gelatin weighed in prescription were properly swollen in water overnight, heated in a water bath, and then prepared as the mixed gel solution A (MGSA); secondly, PVPK-30, CMC-Na, and carbomer-940 were weighed, mixed, swollen, dissolved, heated, and prepared as the mixed gel solution B (MGSB); thirdly, after weighing and mixing glycerol, propylene glycol, and triethanolamine, model drugs were added and stirred until these drugs were completely dissolved as the mixed gel solution C (MGSB); and fourthly, the MGSB and MGSC were added to solution A correspondingly, stirred while being added, and water was added until all solutions weighed 600 g. Solutions were evenly stirred and deposited to remove air bubbles. Finally, the final MGS was quantitatively poured into a rubber ring attached to blank matrix backings (7 cm in diameter), extended and frozen for 2 h, and dried in natural conditions until a total of 30 patches were formed with the same uniform thickness and unified colors. The dosage per patch was 12.5 mg.

2.3. Standard Operation of FCT Penetration Enhancement {#sec2dot3-molecules-22-00525}
------------------------------------------------------

According to TCM theory, the FCT method influencing factors were mainly associated with the cupping method of operation, cupping therapy pressure, and duration time. Therefore, in our research, we designed and fabricated various cups of different sizes ([Figure 3](#molecules-22-00525-f003){ref-type="fig"}) to control the pressure of cupping therapy or regulate the levels of stimulation to human skin. Cup numbers 2, 3, and 4 were selected, and their inner air was evacuated using a syringe through the openings at the top of the Fu's cupping to create and regulate the negative pressure of inner environments ([Figure 3](#molecules-22-00525-f003){ref-type="fig"} and [Figure 4](#molecules-22-00525-f004){ref-type="fig"}).

Moreover, diverse cupping operations followed the TCM clinical operation procedure. *Retaining cupping* keeps the cup on the part to be cupped or retaining cup to follow the meridians (based on TCM theories, meridians are the body channels that contact organs and the body surface, and run Qi, blood, or body fluid; they are also defined as the trunk and branch of Qi, blood, or body fluid circulation in the human body). This is generally for 5\~15 min, preferably 7 min, and with warming the meridians it is also referred to as "warming cupping". "*Shaking cupping*" or "spinning cupping" is defined as follows: the cup on the skin is rhythmically shaken and pulled; however, the cup should be gently shaken (not too fast; once every 2 s) and at an appropriate angle. Time was measured using a stopwatch. "*Moving cupping*" also known as "slipping" or "scraping cupping", is often applied to the larger or muscular parts of lesions. In this method, a layer of massage oil or glycerin is applied and the cup is pressed on the skin with the left hand until it is tightly secured. Then, the cup is pulled with the right hand to make it slip along the meridians, until the skin flushes.

Based on this procedure, the FCT penetration enhancement experiments were divided into three groups ([Table 1](#molecules-22-00525-t001){ref-type="table"}).

3. In Vitro Transdermal Penetration Enhancement Study {#sec3-molecules-22-00525}
=====================================================

3.1. Quantitative Methods {#sec3dot1-molecules-22-00525}
-------------------------

The Agilent 1260 HPLC system (US Agilent, Palo Alto, CA, USA,) was used for quantification with an automated variable-wavelength ultraviolet-visible detector and a C18 chromatographic column (5 μm, 250 mm× 4.6 mm, Diamonsil, Beijing, China). At chromatographic conditions, the mobile phase was composed of a mixture of acetonitrile-0.1% aqueous phosphoric acid (60:40, *v*/*v*), and the analysis was conducted at a flow rate of 1 mL/min with the detection wavelength set at 228 nm at 35 °C.

3.2. In Vitro Transdermal Tests {#sec3dot2-molecules-22-00525}
-------------------------------

We used the Franz in vitro transdermal diffusion device \[[@B15-molecules-22-00525],[@B20-molecules-22-00525]\] to conduct in vitro transdermal experiments \[[@B2-molecules-22-00525]\] with the volume of receiving pool (*V*, 7.0 mL) and contact area (*A*, 2.92 cm^2^), divided into eight groups: the blank group, the 3% Azone group, the 5% Azone group, the diplex chemical penetration enhancers (DCPEs) group including 3% Azone and 5% mint oil , the iontophoresis group, and the FCT groups. Groups were processed as per the requirements of each group, and patches were used to administer drugs.

Firstly, 20% ethanol phosphate buffer saline solution (PBS) was used as the receiver solution, and the skins of SD rats were used as the percutaneous medium; the skin was tightly fit to the patches and fixed on the diffusion pool. Secondly, the receiver solution and its watery environment were completely adjusted to the constant temperature at 37 °C ± 1 °C, and electromagnetically stirred at a constant speed of 320 r/min. Finally, we immediately filled up the control receiver solution after sampling and fully withdrawing at 3 h, 6 h, 9 h, 12 h, 16 h, 24 h, 30 h, and 36 h, respectively. After such treatment, drug concentrations (*C~i~*, μg/mL) of each sample were analyzed at each time point, and the total cumulative penetration amount at all points and cumulative penetration amount per unit area (*Q~A~*, μg/cm^2^) were calculated as shown in Equation (1). $$Q_{A} = \frac{\sum_{i = 1}^{n}Ci \times Vi}{A}$$

4. In Vivo Transdermal Penetration Enhancement {#sec4-molecules-22-00525}
==============================================

4.1. Quantitative Method {#sec4dot1-molecules-22-00525}
------------------------

Analysis was performed on a WATERS Xevo TQ UPLC-MS/MS system (Waters, Milford, MA, USA), where the chromatographic column of ACQUITY UPLC Shield RP (C~18~, 1.7 μm, 2.1 mm × 50 mm, Waters) and the mobile phase of the acetonitrile-0.05% formic acid was used to enable complete separation of target components under gradient elution ([Table 2](#molecules-22-00525-t002){ref-type="table"}). Simultaneously, the total ion chromatograms and quantitative data were recorded and processed using an electrospray ion source \[[@B21-molecules-22-00525]\] under the following mass spectrum conditions: 150 °C ion source temperature, 3.0 KV capillary voltage, and 40 V first cone voltage. The desolventized gas (DG) was N~2~, its temperature was 550 °C, its flow was DG 750 L/h, and the cone gas flow was 50 L/h. The collision gas (CG) was Ar, and the collision gas flow rate was 0.15 mL/min. Furthermore, the indomethacin quantitative ion reaction was as follows: Parent (*m*/*z*) 356.1198→Daughter (*m*/*z*) 111.9691 + Daughter (*m*/*z*) 138.9997; meanwhile, the quantification for naproxen (an internal standard) was Parent (*m*/*z*) 231.1855→Daughter (*m*/*z*) 185.0841 ([Table 3](#molecules-22-00525-t003){ref-type="table"}).

4.2. In Vivo Percutaneous Penetration Enhancement Test {#sec4dot2-molecules-22-00525}
------------------------------------------------------

SD rats were chosen and randomly divided into five groups: the control group, the FCTM group, the FCTL group, the CPE-3% Azone group, and the CPE-5% Azone group. After intraperitoneal injection and anesthesia using 10% urethane, rats were shaved and Shu-back Acupoints were marked and treated as per the corresponding group's requirement. In addition, a work area of 3.14 cm^2^ was selected within the marked part of the skin and was used to administer drugs with dosages of 2.0 mg/rat. The 3% Azone patches were delivered to the chemical enhancer group and the none-enhancer patches were used in the control group; they were used to administer drugs after cupping therapy in the FCT group.

Capillaries with a diameter of 1.0 mm were used to take 0.5 mL of blood from the venous plexus under the rats' eye sockets (sodium treatment was done using heparin); whole blood samples were taken at 1 h, 3 h, 6 h, 9 h, 12 h, 16 h, 20 h, 24 h, 28 h, 36 h, and 48 h, and then placed into anticoagulation *Eppendorf* tubes. Plasma was prepared by centrifugation. Then, 100 μL of rat plasma was mixed with 700 μg of internal standard, and 1 mL of ethyl acetate was added for extraction. The mixture was vortexed for 10 min and then centrifuged at 12,000 rpm for 13 min at 10 °C. Next, 800 μL of supernatant raffinate was transferred into a nitrogen blowing concentrator for evaporation into a residue. This residue was dissolved with 0.5 mL of acetonitrile, used for detection via the UPLC-MS/MS system.

5. Penetration Enhancement Synergism Study {#sec5-molecules-22-00525}
==========================================

The penetration enhancement synergism of the FCT (Method B) and CPE (Method A) were examined using a 3^K^ factorial design: the levels of Method A and B were divided into three grades ([Table 4](#molecules-22-00525-t004){ref-type="table"}); nine groups of experiments were conducted, with three repeated experiments in each group for a total of 27 experiments. After detecting and analyzing with UPLC-MS/MS, the areas under the curve (AUC*~(0--t)~* and AUC*~(0--∞)~*) in the compartment model parameters and the AUMC*~(0--t)~*, AUMC*~(0--∞)~* and the maximum plasma concentration (C*~max~*)under the moment curve in the statistical moment model were used as evaluation indexes for the penetration enhancement synergistic effects, which were denoted as Y~1~, Y~2~, Y~3~, Y~4~, and Y~5~, respectively; the normalization value (Y) of all indexes was calculated according to the following formula: Y = Y~1~/Y~1max~ + Y~2~/Y~2max~ + Y~3~/Y~3max~ + Y~4~/Y~4max~ + Y~5~/Y~5max~ ([Table 5](#molecules-22-00525-t005){ref-type="table"}).

6. Skin Structure Study by SEM and TEM {#sec6-molecules-22-00525}
======================================

6.1. Grouping and Treatment of Animals {#sec6dot1-molecules-22-00525}
--------------------------------------

SD rats were randomly divided into 10 groups: the control group, the FCTL group, the FCTM group, the FCTH group, the CPE-3% Azone group, the CPE-5% Azone group, the FCTL + CPE-3% Azone group, the FCTM + CPE-5% Azone group, the FCTL + CPE-5% Azone group, and the FCTM + CPE-3% Azone group. An electric knife was used to dehair the abdomen and back skin of SD rats. After dehairing, the skin was cleaned with warm water and medical absorbent cotton was used for drying. After observing under a magnifying glass, the skin without any damage was reserved. Furthermore, the FCT groups were treated with the FCT standard operation ([Table 1](#molecules-22-00525-t001){ref-type="table"}) for some time; in the CPE groups, patches with 3% Azone or 5% Azone were stuck to the skin and treated for 12 h; the control group was treated for 12 h using patches without any enhancers.

6.2. Sample Preparation and Observation {#sec6dot2-molecules-22-00525}
---------------------------------------

After animals were treated, skin samples were cut from the treated parts; 4% paraformaldehyde solution was firstly used to fix the sample, and then 2.5% glutaraldehyde was used to solidify them, after which they were placed in a refrigerator for preservation and to solidify at 2\~4 °C for 24 h. The 2 mm × 2 mm tissue block was dehydrated, dried, and subjected to "metal spraying" plating. Then, the surface structure of skin SC was observed by a JSM-6940 SEM (Hitachi, Tokyo, Japan). After the 1 mm × 1 mm tissue block was rinsed, dehydrated, soaked, embedded, and treated in other methods using 0.1 mM/mL phosphate buffered solution, the ultra-thin sections were prepared and stained, and the SC ultrastructures were observed with a Hitachi-7650 TEM (Hitachi).

7. Results {#sec7-molecules-22-00525}
==========

7.1. Analysis of In Vitro Results {#sec7dot1-molecules-22-00525}
---------------------------------

The ratio of cumulative transdermal penetration amount to total dosage of indomethacin, i.e., cumulative penetration percentage (Q%), was calculated according to the in vitro cumulative transdermal penetration amount \[[@B18-molecules-22-00525]\] of indomethacin (Q, μg) at each point; and the "1 − Q%" denoted the remaining dosage percentage of the matrix at different time points. The cumulative penetration percentage (Q%) was used as the y-coordinate, and time was used as the x-coordinate to draw out the Q%-time curve of indomethacin in in vitro percutaneous diffusion tests ([Figure 5](#molecules-22-00525-f005){ref-type="fig"} and [Figure 6](#molecules-22-00525-f006){ref-type="fig"}). Compared with the blank group, Q~A9~ and Q ~A24~, and the enhancement ratio (ER), were calculated at 9 h and 24 h, as shown in [Table 6](#molecules-22-00525-t006){ref-type="table"}. After the experiments, the matrix patch and skin were removed and cut into pieces, and then extracted for 90 min using 50 mL methanol and heating reflux. Then, the indomethacin residual in the matrix patch and skin with each extraction solution was detected to obtain the indomethacin distribution in paste, skin, and receiver solution ([Figure 7](#molecules-22-00525-f007){ref-type="fig"}). In vitro results ([Figure 5](#molecules-22-00525-f005){ref-type="fig"} and [Figure 6](#molecules-22-00525-f006){ref-type="fig"}) showed that FCT had a significant effect on transdermal penetration enhancement. Firstly, compared with the control group, the indomethacin percutaneous ratio ([Figure 7](#molecules-22-00525-f007){ref-type="fig"}) of the FCTL group as a result of penetration enhancement was 35.52%, indicating that the FCTL group, CPE group (33.21%), and iontophoresis group (35.36%) were roughly equivalent with respect to the effects of penetration enhancement. Furthermore, the ER of the FCTL at 9 h was 1.76X that of the control group, showing a significant effect of penetration enhancement ([Table 6](#molecules-22-00525-t006){ref-type="table"}). Secondly, the indomethacin penetration ratios ([Figure 7](#molecules-22-00525-f007){ref-type="fig"}) of the FCTM and FCTH groups were 47.36% and 54.58%, respectively, with ERs at 9 h 3.58X and 8.39X that of the control, respectively. This means that their effects on penetration enhancement were significant and higher than those of the CPEs and iontophoresis groups. Thirdly, the ERs of the FCTM and FCTH groups at 24 h were 2.35X and 1.76X, respectively ([Table 6](#molecules-22-00525-t006){ref-type="table"}), slightly higher than that of the CPEs and iontophoresis groups; nevertheless, the decrease of penetration enhancement intensity appearing in later stages might be associated with the recovery of skin barrier function with time. Thus, the recoverability of skin barrier function after treatment by FCT must be evaluated in subsequent studies. Besides, we found that compared with the control group, the DCPE of 3% Azone + 5% mint oil reduced the IM percutaneous ratio, which was only 14.1%; however, its ER at 9 h was 0.41X, indicating an inhibitory percutaneous effect of DCPEs on indomethacin.

7.2. Analysis of In Vivo Pharmacokinetic Results {#sec7dot2-molecules-22-00525}
------------------------------------------------

According to the blood concentration of each group, the concentration (C, μg/mL)-time (t, h) curve of each group was drawn ([Figure 8](#molecules-22-00525-f008){ref-type="fig"}). The single-compartment model and statistical moment model were adopted to analyze pharmacokinetic results under concentration weight (W = 1). Analysis software Excel and DAS2.0 were combined to calculate and obtain the pharmacokinetic parameters. AUC~(0--t)~ and AUC~(0--∞)~ in the compartment model parameters and AUMC~(0--t)~, AUMC~(0--∞)~, and C ~max~ in the statistical moment model were applied as in vivo evaluation indexes for comparison and analysis of penetration enhancement effects ([Table 7](#molecules-22-00525-t007){ref-type="table"} and [Table 8](#molecules-22-00525-t008){ref-type="table"}).

Findings showed that the C-t curve of the FCTM group was significantly higher than that of any other group, while the C-t curve of the FCTL group was slightly higher than that of the chemical penetration enhancer group. The AUC and AUMC of in vivo percutaneous absorption of FCT penetration enhancement was higher than that of the control group, AUC and AUMC of the FCTL group were slightly higher than that of the CPE group, and the AUC and AUMC of the FCTM group were significantly higher than that of any other group, indicating that FCT had a facilitating effect on IM transdermal absorption.

7.3. Variance Analysis of Synergism Study {#sec7dot3-molecules-22-00525}
-----------------------------------------

Normalization values (Y) of AUC~(0--t)~, AUC~(0--∞)~, AUMC~(0--t)~, AUMC~(0--∞)~, and C~max~ were used as indices ([Table 6](#molecules-22-00525-t006){ref-type="table"}), and Design-Expert 8.0.5 was used for regression and variance analysis. A, B and A × B interaction effects were shown by making a three-dimensional (3-D) chart analysis and visual analysis ([Table 9](#molecules-22-00525-t009){ref-type="table"}, [Figure 9](#molecules-22-00525-f009){ref-type="fig"} and [Figure 10](#molecules-22-00525-f010){ref-type="fig"}).

Findings were as follows: firstly, the variance analysis of regression model (*P* \< 0.0001, [Table 9](#molecules-22-00525-t009){ref-type="table"}) and the multiple correlation coefficient (R^2^ = 0.9856) suggested that this model had a significant difference, indicating that the model was good; secondly, the significance level of A (CPE) was 0.0004 and the difference was markedly significant, indicating that CPE had a markedly significant effect on the experiments; and thirdly, the significance level of B (FCT) was under 0.0001 and the difference was markedly significant, and when combined with the 3-D chart of subjective effects ([Figure 9](#molecules-22-00525-f009){ref-type="fig"}), it had a significant effect on the in vivo percutaneous absorption of indomethacin. Besides, the significance level of A × B interaction was beneath 0.0001 and its difference was markedly significant ([Table 9](#molecules-22-00525-t009){ref-type="table"}), indicating that A × B interaction had a markedly significant effect on the in vivo percutaneous absorption of IM. Combined with the A × B interaction visual chart ([Figure 10](#molecules-22-00525-f010){ref-type="fig"}), this also demonstrated that the combination of FCT and CPEs generated a significant synergistic effect on the penetration enhancement of indomethacin.

7.4. Analysis of SEM Images {#sec7dot4-molecules-22-00525}
---------------------------

SEM images are shown in [Figure 11](#molecules-22-00525-f011){ref-type="fig"}A--J. Control group images indicated that the SC surface cells of SD rats were flat, relatively regular, and closely spaced with some ridgelines and zigzagging arrangement, as shown in the yellow-arrow part ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}A).

In comparison with the control group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}A), the FCTL ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}B) and FCTM ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}C) images had more cracks, and loose and irregular arrangement on the SC surface structure; meanwhile, the SC surface presented some microstructure slices, and skin SC pores grew bigger as indicated by the red circle. Furthermore, with the increase of FCT penetration enhancement, the SC structure fissure grew bigger, as marked by the yellow arrows. The SC surface of SD rats in the FCTH group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}D) was almost completely damaged, and it was hard to observe the complete SC surface structure. This revealed that the dense structure of the SC had been damaged to varying degrees by diverse FCTs, which was probably part of the percutaneous penetration mechanism.

Compared with the control group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}A), the CPE-3% Azone group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}E) and CPE-5% Azone group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}F) had slightly bumpy wrinkles, and relatively loose and irregular arrangement on the flat surface structure of the SC. Additionally, with the increase of CPE penetration enhancement, the SC grew bigger (as marked by the yellow arrows).

In contrast to the FCT groups, the SC surface of SD rats treated by CPEs had internal bumpy wrinkles, clearly shown in [Figure 11](#molecules-22-00525-f011){ref-type="fig"}E,F. There were no significant cracks, and relatively loose arrangement, but less than in the FCT groups; besides, the SC surface pores did not grow bigger (as marked by the red circle).

Compared with the control group ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}A), the skin in the FCT + CPE group after treatment ([Figure 11](#molecules-22-00525-f011){ref-type="fig"}G--J) showed obvious folds and ridges, and this ridge-like structure obviously increased. The SC surface was arranged more irregularly and disorderly. Additionally, the gaps and cracks of SC surface were larger than that of the single FCT group and single penetration enhancer group, indicating that the combination of FCT and chemical penetration enhancers had more significant changes in the SC.

Furthermore, the skin SC from the FCTH group was severely damaged, and the lower portion of the vascular structure (vessels or micrangiums) beneath the SC was observed (marked by the red arrow) ([Figure 12](#molecules-22-00525-f012){ref-type="fig"}). Several areas of skin from all the samples had cracks after 24 h during the in vitro percutaneous absorption experiments, indicating that FCTH significantly decreased the barrier effect of the skin. However, there may be self-recovery of skin barrier function after treatment, and therefore further study is needed to clarify this issue.

7.5. Analysis of TEM Images {#sec7dot5-molecules-22-00525}
---------------------------

The control group (A), FCTL group (B), CPE-3% Azone group (C), and CPE-5% Azone group (D) are shown in [Figure 13](#molecules-22-00525-f013){ref-type="fig"}, respectively.

The control group ([Figure 13](#molecules-22-00525-f013){ref-type="fig"}A) indicated that the keratinocyte SC ultrastructure of normal SD rats had a compact "brick structure", which was regularly and closely arranged, overlaid layer-by-layer, and had densely spaced and flat-shaped lipid composition between the layers. It constituted the complete lipid film with a compact structure, low water content, and high resistance, which has the function of barrier protection and is considered to be the major obstacle to the transdermal absorption of drugs (see yellow arrow).

Compared with the control group, after the treatment of FCT penetration enhancement as shown in [Figure 13](#molecules-22-00525-f013){ref-type="fig"}B, this "brick structure" became loose, the gap increased, and irregular arrangement and lower degree of overlaying were observed. Such changes can reduce the resistance of drug penetration and increase transdermal absorption.

Compared with the control group, the SC ultrastructure after the chemical penetration enhancer treatment ([Figure 13](#molecules-22-00525-f013){ref-type="fig"}C,D) had loose arrangement, and a reduced gap, but this change was less clear than that of the FCT group. Furthermore, the intersecting degree of the keratinized structure was significantly reduced, as indicated by the yellow arrow.

8. Discussion {#sec8-molecules-22-00525}
=============

This research attested through in vitro and in vivo percutaneous experiments, that as a new physical technology for transdermal administration, FCT can enhance IM percutaneous absorption. Meanwhile, the FCT and CPEs had a markedly synergistic effect on penetration enhancement. SEM and TEM results showed that the SC structure significantly changed after treatment, which reduced the barrier function and increased percutaneous absorption of drugs. Thus, we verified that the first action mechanism of FCT is closely interrelated to its physical effects (negative pressure). It may involve some action mechanisms of percutaneous penetration that enhance FCT physical effects as a result of subatmospheric pressure of FCT, making the fissures, keratinocyte proliferation and acidic liquid secretion more evenly scattered on skin epidermis through stimulating effects of heat, force, bioelectricity and other physical factors.

9. Conclusions {#sec9-molecules-22-00525}
==============

Therefore, FCT as a new form of physical technology for transdermal administration with TCM characteristics has a significant effect on penetration enhancement, and has high value for TCM clinical applications. Therefore, it is worth being disseminated and further developed. Its potential mechanism of penetration enhancement and FCT stimulation are closely associated with changes in the SC, and biological regulation of the skin. However, the functional mechanism of penetration enhancement must be further researched by fluorescence micro-imaging techniques, and various TCM model drugs are required to further validate the effects and features of FCT penetration enhancement.
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![Example of Fu´s cupping therapy (FCT) treatment on human skin.](molecules-22-00525-g001){#molecules-22-00525-f001}

![Fu's cupping made of white rubber.](molecules-22-00525-g002){#molecules-22-00525-f002}

![Images of cups numbering 1\~6, Fu's cupping.](molecules-22-00525-g003){#molecules-22-00525-f003}

![Vacuum operation of Fu's cupping.](molecules-22-00525-g004){#molecules-22-00525-f004}

![Cumulative penetration percentage (Q %)-time curve of in vitro percutaneous tests on the reference groups (*n* = 6). (●) CPE-3% Azone group; (■) CPE-5% Azone group; (▲) DCPEs group, the diplex chemical penetration enhancers group including 3% Azone combined with and 5% mint oils; (▼) iontophoresis group; (♦) blank group.](molecules-22-00525-g005){#molecules-22-00525-f005}

![Q%-time curves of in vitro percutaneous tests on the FCT penetration enhancement groups (*n* = 6). (●) FCTL group; (■) FCTM group; (▲) FCTH group; (▼) iontophoresis group; (♦) blank group.](molecules-22-00525-g006){#molecules-22-00525-f006}

![Illustrative diagram of in vitro transdermal drugs distribution. (![](molecules-22-00525-i001.jpg)) indomethacin residual in the matrix patch; (![](molecules-22-00525-i002.jpg)) indomethacin residual in skin; (![](molecules-22-00525-i003.jpg)) transmission indomethacin.](molecules-22-00525-g007){#molecules-22-00525-f007}

![Concentration--time curve of each groups. (●) FCTL group; (■) FCTM group; (♦) Blank group; (▲) CPE-5% Azone group; (▼) CPE-3% Azone group.](molecules-22-00525-g008){#molecules-22-00525-f008}

![3D image of Factor A and B subjective effects: "A1→A3" and "B1→B3" mean that with the levels of Method A and B gradually increasing, the response value (Y), increases significantly.](molecules-22-00525-g009){#molecules-22-00525-f009}

![Illustrative diagram of the Factor A × B interaction: under respective conditions of A1 (the red polyline), A2 (the green polyline), and A2 (the blue polyline), Y increases significantly as the levels of Method B gradually increase (B1→B3). The polylines are not parallel, indicating a significant interaction between A and B.](molecules-22-00525-g010){#molecules-22-00525-f010}

###### 

Scanning electron microscopy (SEM) images (400 × 300 pixels with ×200X resolution) of Sprague-Dawley (SD) rats skin stratum corneum (SC) in each group after the penetration enhancement treatment, were reduced to a size of 60.0 mm × 70.0 mm. (**A**) control group; (**B**) FCTL group; (**C**) FCTM group; (**D**) FCTH group; (**E**) CPE-3% Azone group; (**F**) CPE-5% Azone group; (**G**) FCTL + CPE-3% Azone group; (**H**) FCTM + CPE-5% Azone group; (**I**) FCTL + CPE-5% Azone group; (**J**) FCTM + CPE-3% Azone group.

![](molecules-22-00525-g011a)

![](molecules-22-00525-g011b)

![SEM images of the FCTH group: the inner and outer surfaces of SD rat skin.](molecules-22-00525-g012){#molecules-22-00525-f012}

![SEM images (16 × 3000X) of rat skin SC in each group after the penetration enhancement treatment were obtained from a Hitachi TEM System, and were then reduced to 70.0 mm × 67.8 mm. (**A**) control group; (**B**) FCTL group; (**C**) CPE-3% Azone group; (**D**) CPE-5% Azone group.](molecules-22-00525-g013){#molecules-22-00525-f013}
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###### 

Treatment condition parameters of FCT transdermal penetration enhancement. FCTL: FCT low-intensity group; FCTM: FCT middle-intensity group; FCTH: FCT high-intensity group.

  FCT Groups   Cupping Operation   Cupping Number   Time
  ------------ ------------------- ---------------- ----------
  FCTL         Retaining cupping   2                6.0 min
  FCTM         Shaking cupping     3                11.0 min
  FCTH         Moving cupping      4                15.0 min
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###### 

Gradient change of the mobile phase.

  Time   Flow Rate (mL/min)   Aqueous Phase (%)   Organic Phase (%)   Curve
  ------ -------------------- ------------------- ------------------- -------
  0.0    0.3                  64.0                36.0                6
  1.0    0.3                  54.0                46.0                6
  2.1    0.3                  48.0                52.0                6
  4.5    0.3                  25.0                75.0                6
  5.0    0.3                  10.0                90.0                6
  6.0    0.3                  10.0                90.0                6
  6.5    0.3                  64.0                36.0                6
  7.5    64.0                 36.0                38.0                6
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###### 

Mass spectrum conditions of quantitative ion peak. IM: indomethacin

  Compound      Parent (*m*/*z*)   Daughter (*m*/*z*)   Dwell (s)   Cone (V)   Collision (V)
  ------------- ------------------ -------------------- ----------- ---------- ---------------
  IM number 1   358.1198           138.9997             0.49        18         20
  IM number 2   358.1198           111.9691             0.49        16         48
  Naproxen      231.1855           185.0841             0.49        16         14
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###### 

Factors and levels of Method A and B. CPE: chemical penetration enhancers.

  Levels   CPE (A)         FCT (B)
  -------- --------------- ------------
  1        Blank (A1)      Blank (B1)
  2        3% Azone (A2)   FCTL (B2)
  3        5% Azone (A3)   FCTM (B3)
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###### 

3^K^ factorial design experiments and results (mean, *n* = 3). Y: normalization value.

  No.   Arrangement   Indexes                                                       
  ----- ------------- --------- --------- --------- ---------- ------------ ------- -------
  1     A2            B2        111.719   210.015   2838.514   13,136.654   3.805   3.073
  2     A3            B2        180.273   232.491   4164.901   11,384.695   5.072   3.800
  3     A3            B1        23.021    37.343    526.322    2601.184     0.783   0.594
  4     A2            B3        183.711   246.637   4072.945   11,759.021   7.699   4.176
  5     A1            B2        78.320    168.944   1992.035   17,113.618   2.548   2.678
  6     A3            B3        213.673   287.876   4611.003   12,129.244   7.849   4.613
  7     A2            B2        120.784   206.598   2982.561   9664.643     3.750   2.924
  8     A3            B2        138.879   222.301   3203.711   10,611.719   4.571   3.262
  9     A3            B3        216.276   265.211   4522.868   10,476.852   8.332   4.487
  10    A1            B2        75.333    155.939   1955.883   14,172.779   2.655   2.452
  11    A2            B1        78.905    130.606   1865.553   10,963.154   2.681   2.176
  12    A3            B1        21.087    30.890    534.802    1450.696     0.782   0.497
  13    A3            B1        22.260    31.663    539.604    1243.887     0.779   0.493
  14    A2            B3        167.116   236.699   3990.846   11,035.755   6.723   3.891
  15    A2            B3        176.351   219.040   3875.847   8132.089     6.972   3.706
  16    A3            B2        139.788   233.713   3275.264   11,562.142   4.694   3.391
  17    A1            B2        76.484    148.867   2014.481   8270.574     2.585   2.092
  18    A2            B1        66.105    138.919   1837.867   6682.340     2.331   1.849
  19    A1            B1        56.227    70.071    1479.349   2427.651     2.296   1.234
  20    A1            B3        184.696   257.779   4263.475   9408.590     7.277   4.074
  21    A1            B3        205.119   262.471   4028.318   10,487.270   6.175   4.066
  22    A3            B3        218.340   260.470   4459.897   10,219.833   8.483   4.469
  23    A2            B2        138.911   201.867   3177.125   9951.217     4.199   3.103
  24    A2            B1        68.813    122.355   1846.695   6065.224     2.398   1.778
  25    A1            B3        159.919   225.284   3750.857   10,929.334   5.941   3.667
  26    A1            B1        55.597    70.376    1374.053   1969.218     2.621   1.221
  27    A1            B1        56.397    68.021    1309.445   2121.255     2.436   1.190
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###### 

In vitro percutaneous test data of each group (mean ± standard deviation, *n* = 6). ER: enhancement ratio.

  Group           Q~A9~ (μg/cm^2^)   Q~A24~ (μg/cm^2^)   ER~9~         ER~24~
  --------------- ------------------ ------------------- ------------- -------------
  Blank           23.72 ± 5.60       98.98 ± 12.82       1.06 ± 0.26   1.11 ± 0.30
  3% Azone        70.72 ± 17.22      150.4 ± 22.86       2.98 ± 1.20   1.52 ± 0.27
  5% Azone        62.97 ± 27.53      146.02 ± 34.86      2.65 ± 1.16   1.48 ± 0.35
  DCPEs           9.82 ± 3.66        27.34 ± 5.35        0.36 ± 0.21   0.23 ± 0.12
  Iontophoresis   42.17 ± 12.64      153.89 ± 33.99      1.78 ± 0.53   1.55 ± 0.34
  FCTL            41.79 ± 17.72      156.21 ± 35.56      1.76 ± 0.82   1.58 ± 0.39
  FCTM            84.88 ± 26.37      232.13 ± 35.04      3.58 ± 1.11   2.35 ± 0.35
  FCTH            199.08 ± 14.48     361.54 ± 14.73      8.39 ± 0.61   3.65 ± 0.15
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###### 

Pharmacokinetic parameters of the single-compartment model (mean ± SD, *n* = 5).

  Parameters    Units     Blank Group     FCTL Group          FCTM Group       3% Azone Group
  ------------- --------- --------------- ------------------- ---------------- ----------------
  t~1/2~        h         11.54 ± 2.90    26.98 ± 12.76       12.21 ± 1.43     21.24 ± 2.33
  K~e~          1/h       0.06 ± 0.01     0.03 ± .0.01        0.06 ± 0.01      0.03 ± 0.00
  V~1/F~        L/kg      4.47 ± 357.78   7900.62 ± 2567.20   0.00 ± 0.00      0.01 ± 0.00
  AUC~(0--t)~   μg/mL∙h   60.66 ± 4.77    76.95 ± 3.46        202.54 ± 34.44   69.72 ± 7.37
  AUC~(0--∞)~   μg/mL∙h   74.05 ± 8.66    140.01 ± 2.48       261.05 ± 41.86   128.45 ± 40.35
  K~a~          1/h       0.07 ± 0.01     0.11 ± 0.04         0.07 ± 0.00      0.07 ± 0.03
  t~1/2Ka~      h         9.84 ± 1.94     7.38 ± 1.27         9.47 ± 0.83      14.08 ± 2.35
  T~lag~        h         1.58 ± 0.06     1.98 ± 0.65         1.55 ± 0.37      1.03 ± 0.42
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###### 

Pharmacokinetic parameters of statistical moment model (mean ± standard deviation, *n* = 5).

  Statistical Moment   Units        Blank Group        FCTL Group          FCTM Group            3% Azone Group
  -------------------- ------------ ------------------ ------------------- --------------------- -------------------
  AUC~(0--t)~          μg/mL∙h      60.21 ± 2.56       76.86 ± 6.07        198.72 ± 72.28        69.89 ± 10.13
  AUC~(0--∞)~          μg/mL∙h      71.42 ± 9.80       133.22 ± 61.40      266.93 ± 106.45       135.23 ± 23.07
  AUMC~(0--t)~         μg/mL∙h^2^   1389.21 ± 135.64   1974.49 ± 166.81    4615.58 ± 1490.33     1812.18 ± 148.18
  AUMC~(0--∞)~         μg/mL∙h^2^   2299.00 ± 434.96   9511.82 ± 4546.77   11,145.18 ± 3525.72   7884.63 ± 6115.12
  MRT~(0--t)~          h            23.0 ± 2.0         25.7 ± 0.6          23.5 ± 1.1            26.3 ± 2.1
  MRT~(0--∞)~          h            31.5 ± 3.5         59.6 ± 17.1         40.7 ± 16.0           54.1 ± 16.5
  VRT~(0--t)~          h^2^         125.6 ± 6.5        142.9 ± 18.2        141.3 ± 5.5           143.5 ± 5.5
  VRT~(0--∞)~          h^2^         582.0 ± 619.7      3056.1 ± 4545.2     1111.2 ± 538.5        2671.0 ± 1042.3
  t~1/2z~              h            13.8 ± 9.8         30.3 ± 13.2         17.8 ± 7.5            30.6 ± 5.9
  T~max~               h            18.0 ± 5.2         28.0 ± 2.8          19.2 ± 3.4            24.7 ± 8.9
  C~max~               μg/mL        2.39 ± 0.38        2.61 ± 0.31         8.00 ± 2.15           2.21 ± 0.55
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###### 

Variance analysis of 3K factorial design.

  Source       Sum of Squares   Degree of Freedom   Mean Square   *F* Value   *p* Value   Significance
  ------------ ---------------- ------------------- ------------- ----------- ----------- --------------
  Model        43.85            8                   5.48          145.05      \<0.0001    \*\*\*
  A-A          0.95             2                   0.48          12.62       0.0004      \*\*\*
  B-B          38.43            2                   19.21         508.41      \<0.0001    \*\*\*
  A × B        4.47             4                   1.12          29.59       \<0.0001    \*\*\*
  Pure error   0.68             18                  0.04                                  
  Cor total    44.53            26                                                        

Note: \*\*\*\* *p* \< 0.001 markedly significant difference.
